A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

AG Ken Paxton pushed debunked misinformation about COVID-19 vaccines. What a shame the damage can’t be undone as easily as ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

At the urging of the group Do No Harm, a 2-1 court panel revisted a decision it issued last year holding the organization ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

A federal appeals court revived a lawsuit that a conservative group brought against Pfizer over one of its fellowship programs.

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...